Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aktis-901
- Development stage
- Preclinical
- Lead developer
- Aktis Oncology
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Aktis-901 is a preclinical-stage targeted alpha therapy (TAT) radioconjugate being developed by Aktis Oncology for the treatment of solid tumors. The drug is designed to deliver potent alpha-emitting radioisotopes directly to cancer cells, utilizing the high linear energy transfer of alpha particles to induce lethal double-strand DNA breaks while minimizing damage to surrounding healthy tissue. Although the specific molecular target of Aktis-901 is currently undisclosed by the sponsor, the program leverages Aktis's proprietary platform to optimize the therapeutic index of alpha radiation in oncology.
Beyond the preview
Go deeper on Aktis-901.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aktis-901.